Hu et al. demonstrated that IL-22 inhibits HSC activation and ameliorates liver fibrosis through enhancing expression of miR-200a and reducing expression of β-catenin (Hu et al., 2016). This evidence concerns the gene IL22 and Hepatic fibrosis.